MacuCLEAR, Inc., a Plano, TX-based specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, has raised more than $1m in funds from existing investors.
The company intends to use the funds to complete a pivotal, Phase 3a human efficacy trial for its lead product, MC-1101, which is a topically administered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by increasing ocular blood flow in the choroidal vessels. MacuCLEAR has also entered into a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in the territory.
Founded in 2006 and led by president and CEO Phillip G. Ralston, the company also has a portfolio of other 11 compounds that are being developed for diabetic retinopathy, second-generation treatment for AMD and other vascular diseases of the eye.
FinSMEs
03/01/2012